KLK3 and neoplasm: Lastly, with the increasing use of molecularly targeted and other novel agents, (e.g. 223Ra dichloride, sorafenib, cabozantinib, sipuleucel-T), there may be dissociated anti-tumor and PSA effects, and therefore, the utility of PSA-based response assessment will be limited 31, 32.